Establishment of a human non-small cell lung cancer cell line resistant to gefitinibKOIZUMI, Fumiaki; SHIMOYAMA, Tatsu; TAGUCHI, Fumiko et al.International journal of cancer. 2005, Vol 116, Num 1, pp 36-44, issn 0020-7136, 9 p.Article

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsUEDA, Yutaka; SHIMOYAMA, Tatsu; MURAKAMI, Haruyasu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1101-1109, issn 0344-5704, 9 p.Article

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsYAMAMOTO, Noboru; HORIIKE, Atsushi; FUJISAKA, Yasuhito et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 489-496, issn 0344-5704, 8 p.Article

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptorKIMURA, Hideharu; SAKAI, Kazuko; ARAO, Tokuzo et al.Cancer science. 2007, Vol 98, Num 8, pp 1275-1280, issn 1347-9032, 6 p.Article

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsMURAKAMI, Haruyasu; UEDA, Yutaka; SHIMOYAMA, Tatsu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1119-1128, issn 0344-5704, 10 p.Article

Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFRSHIMOYAMA, Tatsu; KOIZUMI, Fumiaki; FUKUMOTO, Hisao et al.Lung cancer. 2006, Vol 53, Num 1, pp 13-21, issn 0169-5002, 9 p.Article

Translational studies for target-based drugsNISHIO, Kazuto; ARAO, Tokuzo; SHIMOYAMA, Tatsu et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, issn 0344-5704, s90-s93, SUP1Article

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisolYAMAMOTO, Noboru; TAMURA, Tomohide; SHIMIZU, Mikiko et al.Journal of clinical oncology. 2005, Vol 23, Num 6, pp 1061-1069, issn 0732-183X, 9 p.Article

Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patientsPARK, Sarah; SHIMIZU, Chikako; SHIMOYAMA, Tatsu et al.Breast cancer research and treatment. 2006, Vol 99, Num 1, pp 9-17, issn 0167-6806, 9 p.Article

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumorsYAMADA, Yasuhide; TAMURA, Tomohide; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 173-182, issn 0344-5704, 10 p.Article

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 daysYAMADA, Yasuhide; YAMAMOTO, Noboru; SHIMOYAMA, Tatsu et al.Cancer science. 2005, Vol 96, Num 10, pp 721-728, issn 1347-9032, 8 p.Article